Pain News and Research

Latest Pain News and Research

First Edition: May 2, 2012

Today's headlines include a report that House Republican lawmakers want to cut bonuses to states for enrolling low-income kids in Medicaid and the Children's Health Insurance Program.

3 May 2012

CSI third quarter revenues increase 5% to $21.2 million

Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today reported financial results for its fiscal third quarter ended March 31, 2012.

3 May 2012

Physician Therapeutics publishes results from Sentra PM clinical trial

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that manufactures and distributes specialty pharmaceuticals to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the proprietary medical food Sentra PM.

3 May 2012

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

Contemporary form of swaddling recommended to prevent dysplasia in infants

While tight swaddling may provide a newborn infant with a feeling of warmth and security, studies have found that regularly wrapping a child too tightly in a blanket or cloth may lead to an abnormal development of the hip joint, causing the ball of the hip to dislocate from the hip socket.

2 May 2012

FDA permits Percutaneous Surgical Set for minimally invasive laparoscopic abdominal surgery

On April 30, the U.S. Food and Drug Administration today allowed marketing of the first surgical instrument set that can be assembled and disassembled inside the body during surgery.

2 May 2012

Dixie announces new hemp-based Cannabidiol products without THC

Dixie Elixirs and Edibles, Colorado's premier Tetrahydrocannabinol or THC-infused products company, today announced a new line of products which will break entirely new ground for the company in the category of non-THC-infused product development.

2 May 2012

Diagnosis of neonatal abstinence syndrome triples between 2000 and 2009

About one baby is born every hour addicted to opiate drugs in the United States, according to new research from University of Michigan physicians.

2 May 2012

JLGTD to publish results from Cutaneous Lysate study on vulvodynia

The results from Dr. Gilbert G. Donders' MD, PhD study testing Cutaneous Lysate in women suffering from vulvar pain has been accepted for publication in the Journal of Lower Genital Tract Disease.

2 May 2012

Accelerated partial breast irradiation therapy increases risk for subsequent mastectomy

Accelerated partial breast irradiation (APBI) brachytherapy, the localized form of radiation therapy growing increasingly popular as a treatment choice for women with early-stage breast cancer, is associated with higher rate of later mastectomy, increased radiation-related toxicities and post-operative complications, compared to traditional whole breast irradiation (WBI), according to researchers from The University of Texas MD Anderson Cancer Center.

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Sanofi Pasteur announces new quadrivalent influenza vaccine Phase III pediatric data

Sanofi Pasteur, the vaccines division of Sanofi, announced today new Phase III data for its investigational quadrivalent influenza vaccine (QIV) in children 6 months through 8 years of age.

2 May 2012

FDA approves Protalix, Pfizer’s ELELYSO for treatment of type 1 Gaucher disease

Pfizer Inc. and Protalix BioTherapeutics, Inc. announced today that the United States (U.S.) Food and Drug Administration (FDA) approved ELELYSO (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

2 May 2012

DJOFL first quarter net sales increase 11.7% to $278.9 million

DJO Global, Inc., a leading global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC, for the first quarter ended March 31, 2012.

2 May 2012

Electrical brain stimulation technology may prevent migraine attacks

Migraine pain sits at the upper end of the typical pain scale - an angry-red section often labeled "severe." At this intensity, pain is debilitating. Yet many sufferers do not get relief from - or cannot tolerate - over-the-counter and commonly prescribed pain medications.

2 May 2012

SCPC accredits Porter Adventist Hospital as Chest Pain Center

The Society of Chest Pain Centers (SCPC) recently awarded Porter Adventist Hospital full accreditation status as a Chest Pain Center.

2 May 2012

Heart Rhythm Society launches Boston Citywide Awareness Campaign

Massachusetts Governor Deval Patrick has proclaimed May to be Cardiac Arrhythmia Awareness Month, calling attention to the need for greater public awareness throughout the Commonwealth about two serious heart rhythm conditions, atrial fibrillation and sudden cardiac arrest. To support consumer education about these potentially life-threatening disease states, the Heart Rhythm Society (HRS) has launched a Boston Citywide Awareness Campaign to increase knowledge about symptoms, warning signs and available treatment options.

2 May 2012

InSite Vision first quarter total revenues decrease to $2.3 million

InSite Vision Incorporated today reported financial results for the quarter ended March 31, 2012. Total revenues for the first quarter of 2012 were $2.3 million, a decrease of $0.8 million from the same quarter of 2011.

2 May 2012

High-dose glucocorticoids double risk of bacterial infections in children with JIA

Children with juvenile idiopathic arthritis have higher rates of bacterial infection requiring hospitalization, and use of high-dose steroids significantly increases that risk, according to research from the University of Alabama at Birmingham.

2 May 2012

High-dose steroids increase infection risk in children with juvenile idiopathic arthritis

Children with juvenile idiopathic arthritis (JIA) have higher rates of hospitalized bacterial infection than children without JIA according to an observational study appearing in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR).

2 May 2012